文献速递糖尿病

痛性与无痛性糖尿病神经病变患者的脊髓抑制功能障碍

Spinal Inhibitory Dysfunction in Patients With Painful or Painless Diabetic Neuropathy.
PubMed 文献 · Diabetes Care · 2021-06-18

本研究纳入148名参与者(34名健康对照、42名痛性糖尿病神经病变患者、62名无痛性糖尿病神经病变患者),评估H反射频率依赖性抑制(HRDD)及周围神经病变。结果显示,伴神经病理性疼痛的1型或2型糖尿病患者HRDD受损,且与糖尿病类型及神经病变严重程度无关;而无神经病理性疼痛患者HRDD增强。

要点

  • 痛性糖尿病神经病变患者存在脊髓抑制功能障碍,表现为HRDD受损。
  • HRDD受损与糖尿病类型及神经病变存在或严重程度无关。
  • 无神经病理性疼痛的糖尿病患者HRDD增强,可能反映脊髓疼痛抑制机制激活。

核心结论

  • HRDD丢失或受损可能识别出由脊髓抑制系统受损介导的痛性糖尿病神经病变亚群,这类患者可能对靶向脊髓或脊髓上机制的治疗反应最佳。
  • 无疼痛患者HRDD增强可能反映脊髓疼痛抑制机制的参与。

研究设计与样本

  • 研究纳入148名参与者,包括34名健康对照、42名痛性糖尿病神经病变患者和62名无痛性糖尿病神经病变患者。
  • 所有参与者接受HRDD评估及详细的周围神经病变评估,包括神经传导研究、角膜共聚焦显微镜和热阈值测试。

主要发现

  • 与健康对照(P < 0.001)和无痛患者(P < 0.001)相比,伴神经病理性疼痛的1型或2型糖尿病患者HRDD受损。
  • HRDD受损与糖尿病类型及神经病变的存在或严重程度无关。
  • 无神经病理性疼痛的患者与对照相比HRDD增强(P < 0.05)。

临床怎么用

  • HRDD评估可能有助于识别痛性糖尿病神经病变中脊髓抑制系统受损的亚群,从而指导靶向脊髓或脊髓上机制的治疗。
  • 无疼痛患者HRDD增强提示脊髓疼痛抑制机制激活,可能为治疗提供新思路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Impaired rate-dependent depression of the Hoffman reflex (HRDD) is a marker of spinal inhibitory dysfunction and has previously been associated with painful neuropathy in a proof-of-concept study in patients with type 1 diabetes. We have now undertaken an assessment of HRDD in patients with type 1 or type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 148 participants, including 34 healthy control subjects, 42 patients with painful diabetic neuropathy, and 62 patients with diabetic neuropathy without pain, underwent an assessment of HRDD and a detailed assessment of peripheral neuropathy, including nerve conduction studies, corneal confocal microscopy, and thermal threshold testing. RESULTS: Compared with healthy control subjects (P < 0.001) and patients without pain (P < 0.001), we found that HRDD is impaired in patients with type 1 or type 2 diabetes with neuropathic pain. These impairments are unrelated to diabetes type and the presence or severity of neuropathy. In contrast, patients without neuropathic pain (P < 0.05) exhibited enhanced HRDD compared with control subjects. CONCLUSIONS: We suggest that loss or impairment of HRDD may help to identify a subpopulation of patients with painful diabetic neuropathy mediated by impaired spinal inhibitory systems who may respond optimally to therapies that target spinal or supraspinal mechanisms. Enhanced RDD in patients without pain may reflect engagement of spinal pain-suppressing mechanisms.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Worthington A, Kalteniece A, Ferdousi M, et al. Spinal Inhibitory Dysfunction in Patients With Painful or Painless Diabetic Neuropathy. Diabetes Care. 2021. PMID: 34385346. doi:10.2337/dc20-2797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。